What happens after the arbitration concludes? With the Mylan license still in place and not abrogated by the outcome of any arbitration, there is potential to negotiate continued development of the product with Mylan. The commercial opportunity of the daptomycin product is strong. Cubicin® was a >US$1bn best seller for Merck just prior to the loss of US market exclusivity, and a new formulation called Cubicin® RF, which is stable at room temperature and only requires sterile water to reconstitute, has helped maintain the franchise at US$382m in 2017 sales. More broadly, the daptomycin reformulation will have shown the power of TPM® to reformulate large market injectable drugs and with antibiotic drug development now coming back into favour globally thanks to concerns about drug-resistant microbes, there will be other injectables to work on in this space. The global market for injectable antibiotics has been estimated at ~US$9bn39.
POH Price at posting:
1.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)